公开(公告)号：US09046522B2

公开(公告)日：2015-06-02

申请号：US13386536

申请日：2010-07-23

申请人： Miguel Abal Posada ,  Andreas Doll ,  Antonio Gil Moreno ,  Tamara Maes ,  Cristina Perez ,  Jaume Reventós Puigjaner ,  Elisabet Rossell

发明人： Miguel Abal Posada ,  Andreas Doll ,  Antonio Gil Moreno ,  Tamara Maes ,  Cristina Perez ,  Jaume Reventós Puigjaner ,  Elisabet Rossell

IPC分类号： C12Q1/68 ,  G01N33/574 ,  C07K16/30

CPC分类号： G01N33/57442 ,  C07K16/3069 ,  C07K2317/34 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N2800/60

摘要： The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals.

摘要翻译： 本发明涉及令​​人惊奇的发现：对应于ACAA1，AP1M2，CGN，DDR1，EPS8L2，FASTKD1，GMIP，IKBKE，P2RX4，P4HB，PHKG2，PPFIBP2，PPP1R16A，RASSF7，RNF183，SIRT6，TJP3，EFEMP2，S0CS2， 与对照样品相比，DCN与子宫内膜癌患者相比差异表达，因此可用于检测子宫内膜癌。 特别地，这些具有优异的敏感性，特异性和/或分离受影响的非受影响个体的能力的生物标志物。 此外，发明人发现与对照值相比，这些生物标志物在原发性子宫内膜癌肿瘤组织中的差异表达与子宫液样品中的表达水平相关。 因此，这些生物标志物是稳健的，因为它们被发现在受影响个体的几种不同类型的样品中差异表达。

公开(公告)号：US20120122726A1

公开(公告)日：2012-05-17

申请号：US13386536

申请日：2010-07-23

申请人： Miguel Abal Posada ,  Andreas Doll ,  Antonio Gil Moreno ,  Tamara Maes ,  Cristina Perez ,  Jaume Reventós Puigjaner ,  Elisabet Rossell

发明人： Miguel Abal Posada ,  Andreas Doll ,  Antonio Gil Moreno ,  Tamara Maes ,  Cristina Perez ,  Jaume Reventós Puigjaner ,  Elisabet Rossell

IPC分类号： C40B30/04 ,  C12Q1/68 ,  C40B40/10 ,  C07H21/02 ,  C07K16/18 ,  C40B40/06 ,  G01N33/566 ,  C07H21/04

CPC分类号： G01N33/57442 ,  C07K16/3069 ,  C07K2317/34 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N2800/60

摘要： The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals.

摘要翻译： 本发明涉及令​​人惊奇的发现：对应于ACAA1，AP1M2，CGN，DDR1，EPS8L2，FASTKD1，GMIP，IKBKE，P2RX4，P4HB，PHKG2，PPFIBP2，PPP1R16A，RASSF7，RNF183，SIRT6，TJP3，EFEMP2，S0CS2， 与对照样品相比，DCN与子宫内膜癌患者相比差异表达，因此可用于检测子宫内膜癌。 特别地，这些具有优异的敏感性，特异性和/或分离受影响的非受影响个体的能力的生物标志物。 此外，发明人发现与对照值相比，这些生物标志物在原发性子宫内膜癌肿瘤组织中的差异表达与子宫液样品中的表达水平相关。 因此，这些生物标志物是稳健的，因为它们被发现在受影响个体的几种不同类型的样品中差异表达。